Boothbay Fund Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-7,172
Closed -$574K – 2364
2026
Q1
$574K Buy
7,172
+3,971
+124% +$327K 0.01% 1267
2025
Q4
$273K Sell
3,201
-228
-7% -$18.7K ﹤0.01% 1492
2025
Q3
$267K Buy
+3,429
New +$268K ﹤0.01% 1510
2024
Q4
– Sell
-9,770
Closed -$645K – 1618
2024
Q3
$645K Buy
+9,770
New +$710K 0.01% 903
2024
Q2
– Sell
-11,974
Closed -$1.14M – 1627
2024
Q1
$1.14M Buy
+11,974
New +$1.01M 0.02% 715
2023
Q4
– Sell
-6,028
Closed -$418K – 1747
2023
Q3
$418K Buy
+6,028
New +$484K 0.01% 1117
2023
Q2
– Sell
-5,279
Closed -$437K – 1951
2023
Q1
$437K Buy
5,279
+920
+21% +$72.3K 0.01% 1308
2022
Q4
$325K Sell
4,359
-1,512
-26% -$117K 0.01% 1349
2022
Q3
$485K Buy
5,871
+3,693
+170% +$355K 0.01% 1254
2022
Q2
$207K Sell
2,178
-1,145
-34% -$119K 0.01% 1723
2022
Q1
$391K Buy
+3,323
New +$373K 0.01% 1443
2021
Q2
– Sell
-6,178
Closed -$517K – 1923
2021
Q1
$517K Buy
+6,178
New +$522K 0.02% 930
2020
Q1
– Sell
-3,756
Closed -$292K – 910
2019
Q4
$292K Buy
+3,756
New +$293K 0.03% 603
2019
Q3
– Sell
-3,717
Closed -$229K – 807
2019
Q2
$229K Buy
+3,717
New +$225K 0.02% 583
2018
Q1
– Sell
-5,418
Closed -$204K – 738
2017
Q4
$204K Buy
+5,418
New +$199K 0.03% 587
2017
Q1
– Sell
-16,659
Closed -$520K – 802
2016
Q4
$520K Buy
+16,659
New +$540K 0.12% 224

Other funds holding EW

Boothbay Fund Management's EW Position: Q2 2026 in Review

Boothbay Fund Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 7,172 shares — an estimated $574K sold.

Boothbay Fund Management first reported a position in EW in Q4 2016 and held it in 16 quarters. The position peaked at $1.14M in Q1 2024. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Boothbay Fund Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 7,172 Edwards Lifesciences shares in Q2 2026, an estimated $574K.
  • Boothbay Fund Management first reported a position in Edwards Lifesciences in Q4 2016 and held it in 16 quarters.
  • Boothbay Fund Management's Edwards Lifesciences position peaked at $1.14M in Q1 2024.
  • 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.